Speaker discusses modifiable factors that may impact PRP viability
Click Here to Manage Email Alerts
Key takeaways:
- Low-dose aspirin may have an irreversible effect on growth factor expression in platelet-rich plasma.
- Research is underway to identify the right dose of platelet-rich plasma.
NEW ORLEANS — In reviewing modifiable ways to optimize patients to receive platelet-rich plasma injections, Prathap Jayaram, MD, PhD, said some medications, such as NSAIDs, can have an effect growth factor expression.
“We do see that, through COX-1 and COX-2 pathways, even the low-dose aspirin can irreversibly affect growth factor expression,” Jayaram said in his presentation at the Biologic Association Annual Summit.
Although anesthetics can have intra-articular effects and destroy articular cartilage in various spaces, Jayaram said these medications do not seem to affect platelet viability.
“That doesn’t necessarily mean there is no evidence to the effect of all these anesthetics in the joint and how they potentially affect PRP,” Jayaram said.
Previously published research has also shown that needle gauge does not influence PRP viability, according to Jayaram. He added research has shown three injections of PRP had a long-term impact on pain compared with saline, and signs of symptomatic relief have been found as early as 6 weeks after injection.
Although the right dose of PRP is unknown, Jayaram said research is underway to identify the appropriate dosage.
“A few of us in the group have approached this question looking at validated patient-reported outcomes and are in the process of doing a meta-analysis looking at over 4,000 studies with different comparators,” Jayaram said. “I won’t get into all of the methodology, but [there are] highly heterogeneous data in this space with large effect sizes.”
Collapse
Jayaram P. Optimizing the patient to receive PRP. Presented at: Biologic Association Annual Summit; May 6-7, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts